The immuno-oncology drug Tecentriq is reattempting to expand insurance reimbursement to early-stage lung cancer.

According to Dailypharm coverage, Roche Korea's PD-L1 inhibitor Tecentriq (atezolizumab) will be presented to the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee today (July 10).

The specific indication is “postoperative adjuvant therapy after resection and platinum-based chemotherapy for the treatment of patients with PD-L1 TC ≥50% Stage II-IIIA NSCLC.

NSCLC is the leading type of lung cancer, accounting for about 85-90% of lung cancer deaths in Korea. Most patients are diagnosed at locally advanced or metastatic stage